1. Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: Results of a pilot randomized trial
- Author
-
Rossella Marcucci, Francesca Della Pina, Anar Dushpanova, Claudia Saracini, Maria Serena Parri, Jacopo Gianetti, Sergio Berti, and Betti Giusti
- Subjects
Male ,medicine.medical_specialty ,Ticlopidine ,Platelet Function Tests ,medicine.drug_class ,Population ,Myocardial Infarction ,Proton-pump inhibitor ,Pilot Projects ,CYP2C19 ,Gastroenterology ,2-Pyridinylmethylsulfinylbenzimidazoles ,Internal medicine ,medicine ,Humans ,Drug Interactions ,Prospective Studies ,education ,Pantoprazole ,Aged ,education.field_of_study ,business.industry ,Proton Pump Inhibitors ,Middle Aged ,Clopidogrel ,Anesthesia ,Conventional PCI ,Platelet aggregation inhibitor ,Female ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Background The CYP2C19*2 polymorphism is significantly associated with residual platelet reactivity (RPR) and maybe a major confounding factor in studies evaluating pharmacological interactions with clopidogrel. Objectives We sought to evaluate the influence of a proton pump inhibitor (PPI), pantoprazole, indicated as relatively less influent than other PPIs, on the antiplatelet effect of clopidogrel, considering a stratification of the population for the presence of cytochrome 2C19*2 polymorphism. Methods 105 patients with ST elevation myocardial infarction (STEMI), treated with percutaneous coronary angioplasty (PCI) and who received dual antiplatelet therapy, were randomized between pantoprazole (n=54) or ranitidine (n=51). RPR was evaluated by Platelet Function Analyzer-100 (PFA-100) with collagen-epinephrine (CEPI) and collagene-ADP (CADP) cartridges and by light transmitted aggregometry with 10μM adenosin diphosphate (ADP) and 1mM arachidonic acid (AA), on 5 (T0) and 30 (T1) days after PCI. Results Demographic, clinical and procedural data and the prevalence of CYP2C19*2 polymorphism were similar between the two groups. Not statistically differences were observed for CEPI-CT and for the maximal aggregation (MA) values with AA stimulus at both times. We observed a significant increase in MA values with ADP in PPI group at T0 (p=0.01) and T1 (p=0.03). At the multiple regression analysis PPI use remained significantly associated with ADP-MA both at T0 (p=0.05) and T1 (p=0.03). Conclusions This is the first documentation in a randomized trial, after correction for the bias of CYP2C19*2 polymorphism, that pantoprazole increases the ADP-MA in patients treated with dual antiplatelet therapy.
- Published
- 2013